Perdida de Escucha aguada
usando Terapia Hiperbarica

EN QUE ME PUEDE AYUDAR LA OXIGENOTERAPIA

Back pain, pain, figure-1911009. Jpg

REDUCE INFLAMACION

PRODUCE UNA VASOCONSTRICION HIPEROXIGENADA Y TIENE EFECTO ANGIOGENICO AL IGUAL AYUDA CON ARTERIOSCLEROSIS

Corona, sign, symbol-5231110. Jpg

ESTIMULA Y REGULA SISTEMA INMUNOLOGICO

TIENE EFECTO BACTEROSTATICO Y BACTERICIDA ESTIMULANDO EL SISTEMA INMUNOLGICO Y POTENCIALIZA LA ACCION DE ANTIBIOTICOS 

Brain, organ, cerebrum-5605289. Jpg

ESTIMULA FUNCION CEREBRAL

IRRIGANDO EL AREA AFECTADA EN TU CASO

Heart, nurse, health-5079717. Jpg

FAVORECE CIRCULACION

LA MICRO Y MACRO CIRCULACION DE LA OIDO ,CABEZA Y CUERPO MEJORANDO LA OXIGENACION

Hearing, ear, sound-41428. Jpg

MEJRORAR LA ESCUCHA

JUNTO CON EL TRATAMIENTO CONVENCIONAL

Blood pressure, blood, pressure-5095736. Jpg

REGULA PRESION ARTERIAL

TIENE EFECTO VASO REGULADOR, COADYUVANDO CON SU TRATAMIENTO PARA DISMINUIR LA PRESION ARTERIAL 

Close-up, communication, deaf-18753. Jpg

LA OXIGENACIÓN HIPERBÁRICA EN LA PERDIDA DE ESCUCHA IDEOPATICA

La terapia de oxigenación hiperbárica puede utilizarse para la pérdida auditiva neurosensorial súbita idiopática como terapia adyuvante. Puede promover la oxigenación del aparato del oído interno y reactivar la capacidad auditiva. Los pacientes que no responden a los esteroides orales e intratimpánicos pueden beneficiarse de este tratamiento.​

CUANDO EMPEZAR LA TERAPIA

La oxigenoterapia hiperbárica (TOHB) es una opción excelente para el tratamiento de la sordera súbita. Para obtener una respuesta óptima, es crucial comenzar la terapia dentro de las primeras 72 horas o, en su defecto, es más efectiva cuando se inicia dentro de los primeros 7 a 14 días desde la aparición de los síntomas., combinándola con el tratamiento convencional de esteroides. Los estudios han demostrado que después de la tercera semana, los beneficios de la TOHB disminuyen significativamente, lo que reduce las probabilidades de obtener los resultados deseados.

En caso de no haber comenzado la terapia en ese tiempo, aún es posible iniciar la TOHB hasta tres meses después, con algunos resultados positivos. Sin embargo, a partir de los seis meses desde el evento, aunque puede haber alguna mejoría, las probabilidades de éxito con la terapia disminuyen considerablemente. Es por esto que se recomienda iniciar la TOHB lo antes posible para maximizar las posibilidades de recuperación auditiva.

Los protocolos más utilizados incluyen sesiones diarias a presiones de 2.0 a 2.5 ATA durante 60 a 90 minutos, con un total de 10 a 20 sesiones.

Preguntas Frecuentes

Tiempo optimo para empezar la terapia?

El tiempo optimo son las primers 72hrs previas al evento

Me funciona despues de este tiempo?

Si puede haber resultado, sin embargo despues de las primeras 3 semanas va en disminución el resultado que se podrian obtener

Que presiones se necesitan?

Es importante presiones de compresión de entre 2.0 ATA a 2.4 ATA como establecido por la Undersea and Hyperbaric Medical Society Indications

Cuantas sesiones necesito?

La UHMS Normalmente se recomiendan 20 sesiones seguidas como protocolo, sin embargo se puede obtener mejoría en las primeras 3-10 sesiones

Que resultado puedo esperar?

Depende del caso puede variar, tratándolo a tiempo podemos obtener mejores resultado

Me debería esperar a terminar mi tratamiento de esteroides o antibiótico?

No, es importante usar la terapia como coadyuvante o junto con el tratamiento convencional.

UHMS Perdida de Escucha Aguda - Pagina

¿QUE ES LA PERDIDA SUBITA DE LA AUDICION NEUROSENSORIAL?

La pérdida súbita de audición neurosensorial (“oído interno”), comúnmente conocida como sordera súbita, se produce como una pérdida rápida e inexplicable de la audición, ya sea de pronto o en el transcurso de unos días.

​ La sordera súbita ocurre porque algo no funciona en los órganos sensoriales del oído interno. La sordera súbita frecuentemente afecta a solo un oído.
Las personas con sordera súbita a menudo descubren que han perdido la audición al despertarse por la mañana. Otros primero lo notan cuando intentan usar el oído en el que han perdido la audición, como al usar el teléfono. Mientras tanto, otras personas sienten un fuerte sonido explosivo como un “pop”, justo antes de perder la audición.

​Las personas con este trastorno pueden manifestar síntomas como sensación de llenura en el oído, mareos y un timbre o zumbido en los oídos, como tinnitus.

Haz tu cita
Camara hiperbarica monoplaza en guadalajara

CÓMO SIRVE LA OXIGENACIÓN HIPERBÁRICA EN LA PERDIDA DE ESCUCHA AGUDA

Mas detallado con estudios de soporte usando presiones de 2.0 a 2.4 ATA
Investigación

Algunos de los estudios mas importantes:

  1. Revisión Sistemática y Meta-Análisis (2021, JAMA Otolaryngology):

    • Este análisis incluyó 3 ensayos clínicos aleatorizados con un total de 88 participantes en el grupo de TOHB y 62 en el grupo de control. Los resultados mostraron una mejora significativa en la ganancia auditiva promedio y en la probabilidad de recuperación auditiva cuando la TOHB se usó en combinación con esteroides o como terapia adicional. Se concluyó que la TOHB debería considerarse como parte del tratamiento combinado para SSNHL.

  2. Revisión en Frontiers in Neurology (2024):

    • Este análisis revisó estudios que evaluaron la eficacia de la TOHB para la SSNHL, concluyendo que los mejores resultados se obtienen cuando la TOHB se inicia dentro de las dos primeras semanas desde el inicio de la pérdida auditiva. Los protocolos más efectivos implican 10 a 20 sesiones de TOHB a 2.0 ATA durante 60 a 90 minutos, mostrando mejoras significativas en la audición.

  3. Meta-Análisis Cochrane (2012):

    • Esta revisión destaca la eficacia de la TOHB para SSNHL cuando se combina con esteroides. Los estudios incluidos mostraron una mejoría en la audición en pacientes tratados con TOHB, especialmente en aquellos que comenzaron el tratamiento dentro de las primeras dos semanas.

  4. Estudio Retrospectivo Polaco (2024): Este estudio analizó 218 pacientes tratados con TOHB para SSNHL y destacó que aquellos que recibieron el tratamiento dentro de los primeros 10 días tuvieron mejoras significativas en todas las frecuencias auditivas. Los protocolos típicos involucraron más de 15 sesiones con una presión de 2.5 ATA, lo cual demostró ser particularmente útil en pacientes con pérdida auditiva severa (MDPI).

  5. Estudio del Instituto Militar de Medicina en Varsovia (2024): En un estudio en el que participaron 218 pacientes, se encontró que los mejores resultados se obtuvieron cuando la TOHB se inició dentro de las dos primeras semanas del inicio de los síntomas. Las sesiones de 60 a 90 minutos, aplicadas 5 veces por semana a 2.0 ATA, mostraron una mejora significativa en la recuperación auditiva (MDPI).

MAS BIBLIOGRAFÍA 

1. Fetterman BL, Saunders JE, Luxford WM. Prognosis and treatment of sudden sensorineural hearing loss. Am J
Otol. 1996 Jul; 17(4):529–536.
2. O’Malley MR, Haynes DS. Sudden hearing loss. Otolaryngol Clin N Am. 2008;41: 633–649.
3. Haberkamp TJ, Tanyeri HM. Management of idiopathic sudden sensorineural hearing loss. Am J Otol. 1999
Sept;20:587–592.
4. Stachler R, Chandrasekhar S, Archer S, Rosenfeld R, Schwartz S, Barrs D, Brown S, Fife T, Ford P, Ganiats
T, Hollingsworth D, Lewandowski C, Montano J, Saunders J, Tucci D, Valente M, Warren B, Yaremchuk
K, Robertson P. Clinical practice guidelines: sudden hearing loss. Otolayrgology – Head and Neck Surgery.
2012;146:S1-35.
5. Rauch SD. Idiopathic sudden sensorineural hearing loss. N Engl J Med. 2008 Aug 21;359(8):833–840.
6. Byl FM Jr. Sudden hearing loss: eight years’ experience and suggested prognostic table. Laryngoscope. 1984 May; 94
(5 Pt 1): 647–661.
7. Alexander TH, Harris JP. Incidence of sudden sensorineural hearing loss.” Otol Neurotol. 2013;34:1586–1589.
8. Teranishi M, Katayma N, Uchida Y, Tominaga M, Nakashima T. Thirty-year trends in sudden deafness from four
nationwide epidemiological surveys in Japan. Acta Otolaryngol. 2007;127:1259–1265.
9. Klemm E, Deutscher A, Mosges R. A Present investigation of the epidemiology in idiopathic sudden sensorineural
hearing loss.” Larygorhinootologie. 2009;88:524 –527.
10. Hallberg OE. Sudden deafness of obscure origin. Laryngoscope.1956 Oct; 66(10):1237–1267.
11. Byl FM. Seventy-six cases of presumed sudden hearing loss occurring in 1973; prognosis and incidence.
Laryngoscope. 1977 May;87(5 Pt 1):817–825.
12. Mattox DE, Simmons FB. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1977
Jul-Aug; 86(4 Pt 1):463–480.
13. Shaia FT, Sheehy JL. Sudden sensori-neural hearing impairment: a report of 1,220 cases. Layrngoscope. 1976 Mar;
86(3):389–398.
14. Jourdy DN, Donatelli LA, Victor JD, Selesnick SH. Assessment of variation throughout the year in the incidence of
idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2010 Jan;31(1):53–57.
15. Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A doubleblind clinical study.” Arch Otolaryngol. 1980 Dec; 106(12):772–776.
16. Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory
evaluation. Otol Neurotol. 2001 Jan; 22(1):18 –23.
17. Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone + high-dose prednisone
taper) for the treatment of idiopathic sudden sensorineural hearing loss.” Otol Neurotol. 2008 Jun;29(4):453–460.
18. De Kleyn A. Sudden complete or partial loss of function of the octavus system in apparently normal persons. Acta
Otolaryngologica. 1944(32):407–429.
19. Cole RR, Jahrsdoerfer RA. Sudden hearing loss: an update. Am J Otol. 1988 May; 9 (3):211–215.
20. Hughes GB, Freedman MA, Haberkamp TJ, Guay ME. Sudden sensorineural hearing loss. Otolaryngol Clin North
Am. 1996 Jun; 29(3):393–405.
21. Alimoglu Y, Inci E, Edizer DT, Ozdilek A, Aslan M. Efficacy comparison of oral steroid, intratympanic steroid,
hyperbaric oxygen and oral steroid and hyperbaric oygen treatments in idiopathic sudden sensorineural hearing loss
cases. Eur Arch Otorhinolaryngol. 2011 Dec; 268(12):1735–1741.
22. Lamm C, Walliser U, Schumann K, Lamm K. Oxygen partial pressure measurements in the perilymph and the scala
tympani in normo- and hyperbaric conditions. An animal experiment study. HNO. 1988 Sept;35(9):363–366.
23. Lamm K, Lamm C, Lamm H, Schumann K. Simultaneous determinations of oxygen partial pressure in the scala
tympani, electrocochleography and blood pressure measurements in noise stress in guinea pigs. HNO. 1988 Sep;
36(9):367–372.
24. Belal A Jr. Pathology of vascular sensorineural hearing impairment. Laryngoscope. 1980 Nov;90(11 Pt 1):1831–
1839.
25. Yoon TH, Paparella MM, Schachern PA, Alleva M. Histopathology of sudden hearing loss. Laryngoscope. 1990
Jul;100(7):707–715.
26. Pirodda A, Ferri GG, Modugno GC, Borghi C. Systemic hypotension and the development of acute sensorineural
hearing loss in young healthy subjects.” Arch Otolaryngol Head Neck Surg. 2001 Sep;127:1049–1052.
27. Lehnhardt E, Hesch RD. Causes of inner ear deafness: a critique of therapy. HNO. 1980;28:73–79.
28. Maass B. Autonomic nervous system and hearing. Adv Otorhinolaryngol. 1981;27:14–25.
Copyright © 2019 Undersea and Hyperbaric Medical Society, Inc.
29. Pirodda A, Saggese D, Giausa G, Ferri GG, Nascetti S, Gaddi A. Can hypotension episodes cause cochlear damage
in young subjects? Med Hypotheses. 1997;48:195–186.
30. Pirodda A, Feri Gg, Modugno GC, Gaddi A. Hypotension and sensorineural hearing loss: a possible correlation.
Acta Otolaryngol. 1999;119(7):758–762.
31. Kawakami M, Makimoto K, Fukuse S, Takahashi H. Autoregulation of cochlear blood flow. A comparison of
cerebral blood flow with muscular blood flow. Eur Arch Otorhinolaryngol. 1991;248:471–474.
32. Ciccone MM, Cortese F, Pinto m, Di Teo C, Fornarelli F, Gesualdo M, Mezzina A, Sabatelli E, Scicchitano P,
Quaranta N. Endothelial function and cardiovascular risk in patients with idiopathic sudden sensorineural hearing
loss. Atherosclerosis. 2012;225:511–516.
33. Brant LJ, Gordon-Salant S, Pearson JD, Klein LL, Morrell CH, Metter EJ, Fozard JL. Risk factors related to ageassociated hearing loss in the speech frequencies. J Am Acad Audiol. 1996;7:152–160.
34. Rudack C, Langer C, Stoll W, Rust S., Walter M. Vascular risk factors in sudden hearing loss. Thromb Haemost.
2006;95:454–561.
35. Aimoni C, Bianchini C, Borin M, Ciorba A, Fellin R, Martini A, Scanelli G, Volpato S. Diabetes, cardiovascular risk
factors and idiopathic sudden sensorineural hearing loss: a case-control study. Audio Neurotol. 2010;15(2):111–115.
36. Lin HC, Chao PZ, Lee HC. Sudden sensorineural hearing loss increases the risk of stroke: a 5-year follow-up study.
Stroke. 2008 Oct;39 (10):2744–2748.
37. Ozler GS. Increased neutrophil-lymphocyte ratio in patients with idiopathic sudden sensorineural hearing loss. J
Craniofac Surg. 2014 May;25(3): e260–e263.
38. Gloddek B, Lamm K, Arnold W. Pharmacological influence on inner ear endothelial cells in relation to the
pathogenesis of sensorineural hearing loss. Adv Otorhinolaryngol. 2002;59:75–83.
39. Merchant SN, Durand ML, Adams JC. Sudden deafness: is it viral? ORL J Otorhinolaryngol Relat Spec.
2008;70:52–62.
40. Merchant SN, Adams JC, Nadol JB Jr. Pathology and pathophysiology of idiopathic sudden sensorineural hearing
loss. Otol Neurotol. 2005 Mar;26(2):151–160.
41. Stokroos RJ, Albers FW, Schirm J. The etiology of idiopathic sudden sensorineural hearing loss: experimental herpes
simplex virus infection of the inner ear. Am J Otol. 1998 Jul;19(4):447–452.
42. Shirwany NA, Seidman MD, Tang W. Effect of transtympanic injection of steroids on cochlear blood flow, auditory
sensitivity, and histology in the guinea pig. Am J Otol 1998; 19:230 –235.
43. Nagura M, Iwasaki S, Wu R, Mizuta K, Umemura K, Hoshino T. Effects of corticosteroid, contrast medium and
ATP on focal microcirculatory disorders of the cochlea. Eur J Pharmacol. 1999 Jan 29;366(1):47–53.
44. Tabuchi K, Oikawa K, Uemaetomari I, Tsuji S, Wada T, Hara A. Glucocorticoids and dehydroepiandrosterone
sulfate ameliorate ischemia-induced injury of the cochlea. Hear Res. 2003 Jun; 180(1-2):51–56.
45. Lin DW, Trune DR. Breakdown of stria vascularis blood-labyrinth barrier in C3H/lpr autoimmune disease mice.
Otolaryngol Head Neck Surg. 1997 Nov;117(5):530– 534.
46. Trune DR, Wobig RJ, Kempton JB, Hefeneider SH. Steroid treatment improves cochlear function in the MRL.
MpJ-Fas(lpr) autoimmune mouse. Hear Res. 1999 Nov;137(1-2):160–166.
47. Alexiou C, Arnold W, Fauser C, Schratzenstaller B, Gloddek B, Fuhrmann S, Lamm K. Sudden sensorineural
hearing loss: does application of glucocorticoids make sense? Arch Otolaryngol Head Neck Surg. 2001, Mar;
127(3):253-258.
48. Slattery WH, Fisher LM, Iqbal Z, Friedman RA, Liu N. Intratympanic steroid injection for treatment of idiopathic
sudden hearing loss. Otolaryngol Head Neck Surg. 2005 Aug; 133(2):251–259.
49. Dispenza F, Amodio E, De Stefano A, Gallina S, Marchese D, Mathur N, Riggio F. Treatment of sudden
sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. Eur
Arch Otorhinolaryngol. 2011 Sep;268(9):1273-1278.
50. Seggas I, Koltsidopoulos P, Bibas A, Tzonou A, Sismanis A. Intratympanic steroid therapy for sudden hearing loss: a
review of the literature. Otol Neurotol. 2011 Jan; 32(1):29–35.
51. Spear SA, Schwartz SR. Intratympanic steroids for sudden sensorineural hearing loss. A systematic review.
Otolaryngol Head Neck Surg. 2011 Oct;145(4):534–543.
52. Ferri E, Frisina A, Fasson AC, Armato E, Spinato G, and Amadori M. Intratympanic steroid treatment for idiopathic
sudden sensorineural hearing loss after failure of intravenous therapy. ISRN Otolaryngology. 2012;1–6.
53. Haynes DS, O’Malley M, Cohen S, Watford K, Labadie RF. Intratympanic dexamethasone for sudden sensorineural
hearing loss after failure of systemic therapy. Laryngoscope. 2007 Jan;117(1):3–15.
54. Cinamon U, Bendet E, Kronenberg J. Steroids, carbogen or placebo for sudden hearing loss: a prospective doubleblind study. Eur Arch Otorhinolaryngol. 2001 Nov;258(9):477–480.
Copyright © 2019 Undersea and Hyperbaric Medical Society, Inc.
55. Zadeh MH, Storper IS, Spitzer JB. Diagnosis and treatment of sudden-onset sensorineural hearing loss: a study of
51 patients. Otolaryngol Head Neck Surg. 2003 Jan;128(1):92–98.
56. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed
by clinical application. Laryngoscope. 1999 Jul; 109(7 Pt 2):1–17.
57. Bird PA, Begg EJ, Zhang M, Keast AT, Murray DP, Balkany TJ. Intratympanic versus intravenous delivery of
methylprednisolone to cochlear perilymph. Otol Neurotol. 2007 Dec; 28(8):1124–1130.
58. Plontke SK, Biegner T, Kammerer B, Delabar U, Salt AN. Dexamethasone concentration gradients along scala
tympani after application to the round window membrane. Otol Neurotol. 2008 Apr; 29(3):401–406.
59. Wei BPC, Stathopoulos D, O’Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database
of Systematic Reviews. 2013;Issue 7. Art. No.: CD003998.
60. Gao Y, Liu D. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing
loss: a meta-analysis. Eur Arch Otorhinolaryngol. 2016; 273:3699–3711.
61. Qiang Q, Wu X, Yang T, Yang C, Sun H. A comparison between systemic and intratympanic steroid therapies as
initial therapy for idiopathic sudden sensorineural hearing loss: a meta-analysis. Acta Oto-Laryngologica. 2016 Dec
6: 1–8 ISSN:0001-6489.
62. Ho HG, Lin HC, Shu MT, Yang CC, Tsai HT. Effectiveness of intratympanic dexamethasone injection in suddendeafness patients as salvage treatment. Laryngoscope. 2004 Jul;114(7):1184–1189.
63. Xenellis J, Papadimitriou N, Nikolopoulos T, Maragoudakis P, Segas J, Tzagaroulakis A, Ferekidis E. Intratympanic
steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngol Head Neck Surg.
2006 Jun;134(6):940– 945.
64. Ahn JH, Han MW, Kim JH, Chung JW, Yoon TH. Therapeutic effectiveness over time of intratympanic
dexamethasone as salvage treatment of sudden deafness. Acta Otolaryngol. 2008 Feb;128(2):128–131.
65. Kilic R, Safak MA, Oguz H, Kargin S, Demirci M, Samim E, Ozluoglu LN. Intratympanic methylprednisolone for
sudden sensorineural hearing loss. Otol Neurotol. 2007 Apr;28(3):312–316.
66. Plaza G, Herraiz C. Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy.
Otolaryngol Head Neck Surg. 2007 Jul;137(1): 74–78.
67. Hong SM, Park CH, Lee JH. Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment
modality for ISSHL. Otolaryngol Head Neck Surg. 2009 Nov;141(5):579–583.
68. Tsai YJ, Liang JG, Wu WB, Ding YF, Chiang RP, Wu SM. Intratympanic injection with dexamethasone for sudden
sensorineural hearing loss. J Laryngol Otol. 2011 Feb; 125(2):133–137.
69. Cavallazzi GM. Relations between O2 and hearing function. Eds: Marroni A, Oriani G, Wattel F. Proceedings of
International Joint Meeting on Hyperbaric and Underwater Medicine. Milano, Italy. 1996a Sept 4–8; 633–645.
70. Nagahara K, Fisch U, Yagi N. Perilymph oxygenation in sudden and progressive sensorineural hearing loss. Acta
Otolaryngol. 1983 Jul – Aug;96(1–2):57–68.
71. Lamm H. Der einfluss der hperbaren sauerstofftherapie auf den tinnitus und horverlust bei akuten und chronischen
innenohrschaden. Otorhinolaryngol Nova. 1995; 5:161–169.
72. Tsunoo M, Perlman MB. Temporary arterial obstruction. Effects on perilymph oxygen and microphonics. Acta
Otolaryngol. 1969;67:460–466.
73. Schwab B, Flunkert C, Heermann R, Lenarz T. HBO in the therapy of cochlear dysfunctions – first results of a
randomized study. EUBS diving and hyperbaric medicine, collected manuscripts of XXIV Annual Scientific Meeting
of the European Underwater and Baromedical Society. Stockholm: EUBS. 1998:40–42.
74. Fattori B, Berrettini S, Casani A, Nacci A, De Vito A, De Iaco G. Sudden hypoacusis treated with hyperbaric oxygen
therapy: a controlled study. Ear Nose Throat J. 2001 Sept;80(9):655–660.
75. Racic G, Maslovara S, Roje Z, Dogas Z, Tafra R. Hyperbaric oxygen in the treatment of sudden hearing loss. ORL J
Otorhinolaryngol Relat Spec. 2003 Nov–Dec;65(6): 317–320.
76. Dundar K, Gumus T, Ay H, Yetiser S, Ertugrul E. Effectiveness of hyperbaric oxygen on sudden sensorineural
hearing loss: prospective clinical research. J Otolaryngol. 2007 Feb;36(1):32–37.
77. Hoffmann G, Bohmer D, Desloovere C. Hyperbaric oxygenation as a treatment for sudden deafness and acute
tinnitus. Proceedings of the Eleventh International Congress on Hyperbaric Medicine. Flagstaff, AZ: Best Publishing
Company; 1995. Pp:146–151.
78. Lamm K, Lamm H, Arnold W. Effect of hyperbaric oxygen therapy in comparison to conventional or placebo
therapy or no treatment in idiopathic sudden hearing loss, acoustic trauma, noise-induced hearing loss and tinnitus.
A Literature Survey. Adv Otorhinolaryngol. 1998;54:86–89.
79. Marchesi G, Valetti TM, Amer M, Ross M, Tiberti R, Ferani R, Mauro G Di. The HBO effective in sudden hearing
loss treatment. UHMS Meeting Abstracts, 2000. http://archive.rubicon-foundation.org/6781.
Copyright © 2019 Undersea and Hyperbaric Medical Society, Inc.
80. Murakawa T, Kosaka M, Mori Y, Fukazawa M, Misaki K. Treatment of 533 patients with sudden deafness
performed oxygenation at high pressure. Nihon Jibiinkoka Gakkai Kaiho. 2000 May;103(5):506–515.
81. Muzzi E, Zennaro B, Visentin R, Soldano F, Sacilotto C. Hyperbaric oxygen therapy as salvage treatment for sudden
sensorineural hearing loss: review of rationale and preliminary report. J Laryngol Otol. 2010;124(2):e2.
82. Ohno K, Noguchi Y, Kawashima Y, Yagishita K, Kitamura K. Secondary hyperbaric oxygen therapy for idiopathic
sudden sensorineural hearing loss in the subacute and chronic phases. J Med Dent Sci. 2010;57(2):127–132.
83. Cvorovic L, Jovanovic MG, Milutinovic Z, Arsovic N, Djeric D. Randomized prospective trial of hyperbaric oxygen
therapy and intratympanic steroid injection as salvage treatment of sudden sensorineural hearing loss. Otol and
Neurotology. 2013;34(6):1021–1026.
84. Yang CH, Wu RW, Hwang CF. Comparison of intratympanic steroid injection, hyperbaric oxygen and combination
therapy in refractory sudden sensorineural hearing loss. Otol and Neurotology. 2013;34:1411–1416.
85. Pezzoli M, Magnano M, Maffi L, Pezzoli L, Marcato P, Orione M, Cupi D, Bongioannini G. Hyperbaric oxygen
therapy as salvage treatment for sudden sensorineural hearing loss: a prospective controlled study. Eur Arch
Otorhinolaryngol. 2015 Jul; 272(7):1659–1666.
86. Schumann K, Lamm K, Hettich M. Effect and effectiveness of hyperbaric oxygen therapy in chronic hearing
disorders. Report of 557 cases 1989. HNO. 1990 Nov; 38(11):408–411.
87. Hoffman G, Bohmer D, Desloovere C. Hyperbaric oxygenation as a treatment of chronic forms of inner ear hearing
loss and tinnitus. Proceedings of the Eleventh International Congress on Hyperbaric Medicine. Flagstaff, AZ: Best
Publishing Company; 1995. Pp:141–145.
88. Kramer MR, Springer C, Berkman N, Glazer M, Bubil M, Bar-Yishay E, Godfrey S. Rehabilitation of hypoxemic
patients with COPD at low altitude at the dead sea, the lowest place on earth. Chest. 1998 Mar;113(3):571–575.
89. Dean JB, Mulkey DK. Continuous Intracellular recordings from mammalian neurons exposed to hyperbaric helium,
oxygen, or air. J Appl Physiol. 2000 Aug 89 (2):807–822.
90. Kau RJ, Sendtner-Gress K, Ganzer U, Arnold W. Effectiveness of hyperbaric oxygen therapy in patients with acute
and chronic cochlear disorders. ORL J Otorhinolarygnol Relat Spec. 1997 Mar–Apr; 59(2):78-83.
91. Giger HL. Therapy of sudden deafness with O2 / CO2 inhalation. HNO. 1979 Mar; 27(3):107–109.
92. Goto F, Fujiita T, Kitani Y, Kanno M, Kamei T, Ishii H. Hyperbaric oxygen and stellate ganglion blocks for
idiopathic sudden hearing loss. Acta Otolaryngol. 1979;88(5– 6):335–342.
93. Pilgramm M, Lamm H. Schumann K. Hyperbaric oxygen therapy in sudden deafness. Laryngol, Rhinol, Otol. 1985
Jul;64(7):351–354.
94. Dauman R, Poisot D, Cros AM, Zennaro O, Bertrand B, Duclos JY, Esteban D, Milacic M, Boudey C, Bebear JP.
Sudden deafness: a randomized comparative study of 2 administration modalities of hyperbaric oxygenotherapy
combined with naftidrofuryl. Rev Laryngol Otol Rhinol (Bord). 1993;114(1):53–58.
95. Zennaro O, Dauman R, Poisot A, Esteben D, Duclose JY, Bertrand B, Cros AM, Milacic M, Bebear JP. Value
of the association of normovolemic dilution and hyperbaric oxygenation in the treatment of sudden deafness. A
retrospective study. Ann Otolaryngol Cir Cervicofac. 1993;110(3):162–169.
96. Cavallazzi G, Pignataro L, Capaccio P. Italian experience in hyperbaric oxygen therapy for idiopathic sudden
sensorineural hearing loss. Proceedings of the International Joint Meeting on Hyperbaric and Underwater Medicine.
Bologna: Grafica Victoria; 1996. Pp: 647–649.
97. Aslan I, Oysu C, Veyseller B, Baserer N. Does the addition of hyperbaric oxygen therapy to the conventional
treatment modalities influence the outcome of sudden deafness? Otolaryngol Head Neck Surg. 2002
Feb;126(2):121–126.
98. Topuz E, Yigit O, Cinar U, Seven H. Should hyperbaric oxygen be added to treatment in idiopathic sudden
sensorineural hearing loss? Eur Arch Otorhinolaryngol. 2004 Aug;261(7)393–396.
99. Narozny W, Kuczkowski J, Kot J, Stankiewicz C, Sicko Z, Mikaszeweski B. Prognostic factors in sudden
sensorineural hearing loss: our experience and a review of the literature. Ann Otol Rhinol Laryngol. 2006
Jul;115(7):553–558.
100. Suzuki H, Fujimura T, Shiomori T, Ohbuchi T, Kitamura T, Hashida K, Udaka T. Prostaglandin E1 versus steroid in
combination with hyperbaric oxygen therapy for idiopathic sudden sensorineural hearing loss. Auris Nasus Larynx.
2008 Jun;35 (2):192–197.
101. Suzuki H, Fujimura T, Ikeda K, Shiomori T, Udaka T, Ohbuchi T, Nagatani G. Prostaglandin E1 in combination
with hyperbaric oxygen therapy for idiopathic sudden sensorineural hearing loss. Acta Otolaryngol. 2008
Jan;128(1):61–65.
102. Cekin E, Cincik H, Ulubil SA, Gungor A. Effectiveness of hyperbaric oxygen therapy in management of sudden
hearing loss. J Laryngol Otol. 2009;123:609–612.
Copyright © 2019 Undersea and Hyperbaric Medical Society, Inc.
103. Liu Y, Sun D, Shao S, Jiang W, Sun Z, Li Z. The effect of hyperbaric oxygen therapy to different degree of hearing
loss and types of threshold curve in sudden deafness patients. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.
2010 Oct; 24(19):890– 894.
104. Korpinar S, Alkan Z, Yigit O, Gor AP, Toklu AS, Cakir B, Soyuyuce OG, Ozkul H. Factors influencing the outcome
of idiopathic sudden sensorineural hearing loss treated with hyperbaric oxygen therapy. Eur Arch Otorhinolaryngol.
2011 Jan; 268 (1):41–47.
105. Holy R, Navara M, Dosel P, Fundova P, Prazenica P, Hahn A. Hyperbaric oxygen therapy in idiopathic sudden
sensorineural hearing loss (ISSHL) in association with combined treatment. Undersea Hyperb Med. 2011 Mar –
Apr;38(2):137–142.
106. Liu SC, Kang BH, Lee JC, Lin YS, Huang KL, Liu DW, Su WF, Kao CH, Chu YH, Chen HC, Wang CH.
Comparison of therapeutic results in sudden sensorineural hearing loss with/without additional hyperbaric oxygen
therapy: a retrospective review of 465 audiologically controlled cases. Clin Otolaryngol. 2011 Apr;36(2):121–128.
107. Fujimura T, Suzuki H, Shiomori T, Udaka T, Mori T. Hyperbaric oxygen and steroid therapy for idiopathic sudden
sensorineural hearing loss. Eur Arch Otorhinolaryngol. 2007 Aug;264(8):861–866.
108. Suzuki H, Mori T, Hashida K, Shibata M, Nguyen KH, Wakasugi T, Hohchi N. Prediction model for
hearing outcome in patients with idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol.
2011;268(4):497–500.
109. Filipo R, Attanasio G, Viccaro M, Russo FY, Mancini P, Rocco M, Pietropaoli P, Covelli E. Hyperbaric oxygen
therapy with short duration intratympanic steroid therapy for sudden hearing loss. Acta Otolaryngol. 2012
May;132(5):475–481.
110. Capuano L, Cavaliere M, Parente G, Damiano A, Pezzuti G, Lopardo D, Lemma M. Hyperbaric oxygen for idiopathic
sudden hearing loss: is the routine application helpful? Acta Oto-Laryngologica. 2015 Jul;135(7):692–697.
111. Carneiro SN, Guerreiro DV, Cunha AM, Camacho OF, Aguiar IC. Hyperbaric oxygen therapy in sudden sensorineural
hearing loss following spinal anesthesia: case reports. Undersea Hyperb Med. 2016;43(2):153 –159.
112. Hosokawa S, Sugiyama K, Takashashi G, Takebayashi S, Mineta H. Prognostic factors for idiopathic sudden
sensorineural hearing loss treated with hyperbaric oxygen therapy and intravenous steroids. J Laryngol and Otol.
2017;131:77–82.
113. Bennett MH, Kertesz T, Perleth M, Yeung P, Lehm JP. Hyperbaric oxygen for idiopathic sudden sensorineural
hearing loss and tinnitus. Cochrane Database Syst Rev. 2012; Issue 10. Art. No.:CD004739.
114. Yildirim E, Murat Ozcan K, Palah M, Ali Cetin M, Ensari S, Dere H. Prognostic effect of hyperbaric oxygen
therapy starting time for sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol. 2015;272:23–28.
115. Bennett MH, Kertesz T, Yeung P. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus.
Cochrane Database Syst Rev. 2005 Jan 25 (1):CD004739.
116. Bennett MH, Kertesz T, Yeung P. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus.
Cochrane Database Syst Rev. 2007 Jan 24 (1):CD004739.
117. Bennett MH, Kertesz T, Matthias P, Yeung P. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss
and tinnitus. Cochrane Database Syst Rev. 2010 Jan 20(1):CD004739.
118. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss. A systematic review. Arch Otolaryngol Head
Neck Surg. 2008 Jun;133:573–581.
119. Agarwal L, Pothier Dd. Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss.
Cochrane Database Syst Rev. 2009 Oct 7;(4): CD003422.
120. Tucci DL, Farmer JC, Kitch RD, Witsell DL. Treatment of sudden sensorineural hearing loss with systemic steroids
and valaciclovir. Otol Neurotol. 2002;23:301– 308.
121. Stokroos RJ, Albers FWJ, Tenvergert EM. Antiviral treatment of idiopathic sudden sensorineural hearing loss: a
prospective, randomized, double-blinded clinical trial. Acta Otolaryngol. 1998b;118: 488–485.
122. Westerlaken BO, Stokroos RJ, Dhooge IJ, Wit HP, Albers FW. Treatment of idiopathic sudden sensorineural hearing
loss with antiviral therapy: a prospective, randomized, double-blind clinical trial. Ann Otol Rhinol Laryngol.
2003;112:993– 100.
123. Uri N, Doweck I, Cohen-Kerem R, Greenberg E. Acyclovir in the treatment of idiopathic sudden sensorineural
hearing loss. Otolaryngol Head Neck Surg. 2003; 128:544–549.
124. Awad Z, Huins C, Pothier DD. Antivirals for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst
Rev. 2012 Aug 15;(8):1–22.
125. Wei BP, Mubiru S, O’Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst
Rev. 2006 Jan 25;(1):CD003998.
126. Nosrati-Zarenoe R, Hultcrantz E. Corticosteroid Treatment of Idiopathic Sudden sensorineural hearing loss:
randomized triple-blind placebo-controlled trial. Otol Neurotol. 2012 Jun; 22(4):523–531.
Copyright © 2019 Undersea and Hyperbaric Medical Society, Inc.
127. Plontke SK, Meisner C, Caye-Thomasen P, Parnes L, Agrawal S, Mikulee T. Intratympanic glucocorticoids for
sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2009 Oct 7(1):CD0088080.
128. Kranke P, Bennett MH, Debus SE, Roeckl-Wiedmann I, Schnabel A. Hyperbaric oxygen therapy for chronic
wounds. Cochrane Database Syst Rev. 2009 Jul 8(1): CD004123.
129. Piper SM, Murphy-Lavoie H, LeGros TL. Idiopathic sudden sensorineural hearing loss. In: Hyperbaric Oxygen
Therapy Indications: The Hyperbaric Oxygen Therapy Committee Report. North Palm Beach, Florida; 2014. Best
Publishing Company.
130. Uzun G, Mutluoglu M, Metin S. The use of hyperbaric oxygen treatment for sudden sensorineural hearing loss in
europe. Diving Hyperb Med. 2016 Mar;46 (1):43– 46.
131. Grades of Hearing Impairment. World Health Organization. 2011. http://www.who.int/pbd/deafness/hearing_
impairment_grades/en/index.html.
132. Deafness and Hearing Impairment. World Health Organization Fact Sheet. April 2010. http://www.who.int/
mediacentre/facsheets/fs300/en/index.html.
133. World Health Organization. The Global Burden of Disease: 2004 Update. 2008. WHO, Geneva, Switzerland.
WHO Press. ISBN 978 92 4 156371 0.
134. Narozny W, Sicko Z, Przewony T, Stankiewicz C, Kot J, Kuczkowski J. Sudden sensorineural hearing loss: a treatment
protocol including glucocorticoids and hyperbaric oxygen therapy. Otolarlyngol Pol. 2004;58(4): 821-830.